CathWorks Submits FFRangio System to FDA for Review and Clearance

 

August 31, 2018—Israel-based CathWorks Ltd. announced that it has submitted its noninvasive fractional flow reserve (FFR) platform, the FFRangio system, to the FDA for review and 510(k) market clearance in the United States. The company expects to receive clearance by the end of 2018.

The FFRangio system is designed to quickly and precisely deliver objective multivessel physiologic measurements to cost-effectively optimize and confirm intraprocedural percutaneous coronary intervention therapy decisions.

The company stated that the submission was made possible with the early completion of full enrollment of the FAST-FFR trial, which was announced on August 16.

The FFRangio system is in development and is not yet FDA cleared or available for sale in the United States, advised the company.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.